CytomX Therapeutics's total assets for Q2 2025 were $175.06M, an increase of 77.73% from the previous quarter. CTMX total liabilities were $55.15M for the fiscal quarter, a -24.92% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.